Novartis (NYSE: NVS) announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Approval Type | New indication approval |
| Product | Cosentyx (secukinumab) 150 mg |
| Indication | Adult patients with polymyalgia rheumatica (PMR) with inadequate response to corticosteroids or intolerance of corticosteroid taper |
| Approval Date | 17 Nov 2026 |
| Basis of Approval | Phase 3 REPLENISH trial |
Drug Profile & Mechanism of Action
- Molecule: Secukinumab, a fully human biologic that directly inhibits interleukin‑17A (IL‑17A), a key pro‑inflammatory cytokine implicated in immune‑mediated inflammatory diseases.
- PMR Context: Polymyalgia rheumatica is an inflammatory rheumatic condition primarily affecting older adults; corticosteroids have long been the mainstay of treatment, but relapse on taper and cumulative steroid toxicity create substantial unmet need — the population now addressed by Cosentyx.
- Adult Franchise: Cosentyx is approved in adults for psoriatic arthritis (PsA), moderate‑to‑severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non‑radiographic axial spondyloarthritis (nr‑axSpA), hidradenitis suppurativa (HS), and now polymyalgia rheumatica (PMR).
- Pediatric Franchise: The biologic is also approved for pediatric patients, including PsO, juvenile idiopathic arthritis subtypes such as juvenile psoriatic arthritis (JPsA) and enthesitis‑related arthritis (ERA) — and in the US for pediatric patients aged 12 years and older with moderate‑to‑severe HS and for juvenile AS.
Clinical Evidence – Phase 3 REPLENISH Trial
| Endpoint | Result (Cosentyx) | Comparator | Relative Benefit |
|---|---|---|---|
| Sustained Remission | Doubled sustained remission rates (specific rates not disclosed in announcement) | Placebo | 2× sustained remission |
| Steroid‑Sparing Effect | Demonstrated corticosteroid‑sparing effect | Placebo | Reduced reliance on steroid therapy |
The approval is based on the pivotal Phase 3 REPLENISH trial, in which Cosentyx doubled sustained remission rates and demonstrated steroid‑sparing effects versus placebo — directly addressing the two core challenges of PMR management: maintaining remission while minimizing cumulative corticosteroid exposure. Full trial design details, patient numbers, and endpoint magnitudes were not disclosed in the announcement.
Market Impact & Outlook
- PMR Treatment Landscape: With corticosteroids the longstanding standard of care, an IL‑17A inhibitor offering sustained remission and steroid‑sparing benefits represents a meaningful therapeutic shift for elderly PMR patients vulnerable to steroid‑related morbidity.
- Franchise Expansion: PMR becomes another indication in Cosentyx’s broad immunology portfolio — spanning dermatology, rheumatology, and now steroid‑refractory PMR — reinforcing Novartis’ leadership in IL‑17A‑targeted therapy and extending the brand’s lifecycle.
- Strategic Depth: The added indication broadens Cosentyx’s addressable patient population and strengthens Novartis’ immunology growth platform against IL‑17, IL‑23, and JAK‑inhibitor competitors.
- Commercial Details: US launch timing, pricing, and ex‑US regulatory submissions for the PMR indication were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of Cosentyx in polymyalgia rheumatica, market adoption, and future regulatory filings. Actual results may differ materially due to risks including reimbursement outcomes, prescribing patterns in rheumatology, competitive therapies, and evolving treatment guidelines for PMR.-Fineline Info & Tech
